Skip to main content

Symbicort News

FDA Medwatch Alert: Long-Acting Beta agonists (LABAs) and Inhaled Corticosteroids (ICS): Drug Safety Communication - Boxed Warning About Asthma-Related Death Removed

ISSUE: FDA's most prominent warning, the Boxed Warning, about asthma-related death has been removed from the drug labels of medicines that contain both an ICS and LABA. A FDA review of four large...

Symbicort Approved for the Treatment of Asthma in Patients 6 to 12 Years of Age

26 January 2017 – AstraZeneca today announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of pediatric exclusivity for Symbicort (budesonide/formoterol)...

FDA Medwatch Alert: Long-Acting Beta-Agonists (LABAs): New Safe Use Requirements

[UPDATED 04-15-2011] To further evaluate the safety of Long-Acting Beta-Agonists (LABAs) when used in combination with inhaled corticosteroids for the treatment of asthma, the FDA is requiring the...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Asthma - Maintenance, Chronic Obstructive Pulmonary Disease

Symbicort patient information at Drugs.com